Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Dow
Express Scripts
Boehringer Ingelheim
McKesson

Last Updated: March 27, 2023

Litigation Details for In Re Koninklijke Philips Patent Litigation (N.D. Cal. 2018)


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


In Re Koninklijke Philips Patent Litigation (N.D. Cal. 2018)

Docket See Plans and Pricing Date Filed 2018-04-03
Court District Court, N.D. California Date Terminated 2021-01-28
Cause 35:271 Patent Infringement Assigned To Haywood Stirling Gilliam Jr.
Jury Demand Plaintiff Referred To Alex G. Tse
Parties ACER AMERICA CORPORATION; ACER INC.; MICROSOFT CORPORATION; MICROSOFT MOBILE OY; YIFANG USA, INC.
Patents 10,123,876; 10,150,827; 10,314,886; 10,369,077; 10,369,113; 10,369,114; 10,369,161; 10,369,168; 10,377,797; 10,377,809; 10,385,105; 10,406,102; 10,406,128; 10,441,639; 10,488,413; 10,596,101; 10,596,107; 10,617,742; 10,624,846; 10,624,875; 10,626,100; 10,626,151; 10,631,974; 10,632,123; 10,632,251; 6,361,817; 6,436,713; 6,565,870; 6,616,771; 6,806,078; 6,858,398; 6,872,397; 6,887,832; 6,902,548; 6,902,550; 6,913,932; 6,951,844; 6,969,514; 7,014,990; 7,022,014; 7,097,860; 7,144,857; 7,318,325; 7,536,215; 7,622,102; 7,718,128; 7,774,978; 7,786,052; 7,795,414; 7,807,873; 7,811,587; 7,901,905; 7,928,052; 7,932,026; 7,976,886; 7,989,477; 8,039,009; 8,057,811; 8,062,632; 8,088,789; 8,127,839; 8,143,237; 8,143,247; 8,247,397; 8,318,674; 8,361,955; 8,377,902; 8,389,215; 8,394,076; 8,420,792; 8,435,951; 8,436,149; 8,491,893; 8,529,898; 8,536,200; 8,574,855; 8,673,574; 8,674,176; 8,679,061; 8,778,620; 8,778,622; 8,785,385; 8,785,415; 8,808,786; 8,809,378; 8,835,622; 8,840,887; 8,840,915; 8,846,344; 8,889,831; 8,962,010; 8,962,034; 8,962,860; 8,969,024; 8,969,064; 8,969,414; 9,017,726; 9,045,536; 9,045,809; 9,067,990; 9,096,840; 9,102,573; 9,107,960; 9,108,949; 9,161,978; 9,168,436; 9,248,187; 9,248,200; 9,265,724; 9,265,827; 9,297,018; 9,314,475; 9,381,247; 9,393,255; 9,393,307; 9,414,599; 9,441,241; 9,447,106; 9,447,108; 9,566,286; 9,580,488; 9,598,718; 9,616,126; 9,707,303; 9,724,271; 9,724,394; 9,752,103; 9,795,389; 9,839,626; 9,902,918; 9,907,783; 9,909,047; 9,909,084; 9,913,489; 9,913,910; 9,915,643; 9,969,786; 9,976,098; RE43,258
Attorneys Aaron P Maurer; Amy Marie Bailey; Andrew Colin Mayo; Andrew Russell; Andrew V. Trask; Antoine M McNamara; Brian P. Wikner; Bruce R Genderson; Chad S. Campbell; Christina J McCullough; Christina Jordan McCullough; Christopher Alan Suarez; Christopher Scott Geyer; Craig R. Kaufman; David M. Fry; David M. Krinsky; Derek S. Neilson; Eleanor Gail Tennyson; Erika H. Warren; Erika Mayo; Hsiang James H Lin; Irene Inkyu Yang; Jared W. Crop; John W Shaw; Kaiwen Tseng; Karen Elizabeth Keller; Kevin Hardy; Kyle Thomason; Lucian C. Chen; Matthew S. Warren; Matthew Warren; Michael J Newton; Michael J. Bettinger; Michael Junwhan Song; Nathan Roger Hoeschen; Patrick Fitch; Patrick J. Flinn; Patrick J. McKeever; Patrick John McKeever; Patrick M. Shields; Patrick Shields; Ramsey M. Al-Salam; Richard A. Cederoth; Rodger Dallery Smith , II; Ross R. Barton; Sanjiv Prakash Laud; Sarah E. Stahnke; Sarah Elizabeth Fowler; Steven J. Balick; Theresa H Nguyen; Tiffany Patrice Cunningham; Tiffany Patrice Cunningham ,; Wing K. Chiu; Xavier Mark Brandwajn
Firms Alston & Bird LLP; Alston and Bird LLP; Alston Bird, LLP Dallas; Antoine M McNamara; Kevin Hardy; Kyle Thomason; LTL Attorneys LLP; Lucian C. Chen ,; Morris, Nichols, Arsht & Tunnell; Perkins Coie LLP; Perkins Colie LLP; Shaw Keller LLP; Sidley Austin LLP; Steptoe & Johnson LLP; TechKnowledge Law Group LLP; Warren Lex LLP; Williams & Connolly LLP; Wing K. Chiu ,
Link to Docket External link to docket
Small Molecule Drugs cited in In Re Koninklijke Philips Patent Litigation
Biologic Drugs cited in In Re Koninklijke Philips Patent Litigation

The biologic drugs covered by the patents cited in this case are See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , and See Plans and Pricing .

Details for In Re Koninklijke Philips Patent Litigation (N.D. Cal. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-09-24 486 Filed 09/24/18 Page 8 of 9 297-18; 1888-401- … 9 In Re Koninklijke Philips Patent Litigation 3 April 2018 29 January…January 2021 4:18-cv-01885 830 Patent Plaintiff District Court, N.D. California External link to document
2018-11-01 534 this document is attached as 21 Exhibit 7. 22 14. On March 28, 2017, the parties submitted…Koninklijke Philips Patent Litigation 3 April 2018 4:18-cv-01885 830 Patent Plaintiff…MOTION FOR LEAVE TO 22 In Re Koninklijke Philips Patent Litigation AMEND ITS INFRINGEMENT … functionality accused of 11 infringing the patents-in-suit, as well as a non-limiting list of touchscreen…specific lists. For example, with respect to the ’913 patent, the accused 13 products were defined as: 14 External link to document
2018-11-21 559 Exhibit 2 to Declaration of Ryan McBrayer 87898 !"# $ 88 8 8 $8 %&8 $8 8 '9 $8 '8 988 8 (8) 8*+ *,++--.7(- … 8 ' $889 8 $88 8 $88 8 0#888 8 ' $ 9 8 0 $888 88 $889 8 8 # #8 -7$8…9898 8 8' 8# 9 '88 9988 8-; '9 8 08 ' $88-; 0$8 0 $8 8 8 '8 8 …Koninklijke Philips Patent Litigation 3 April 2018 4:18-cv-01885 830 Patent Plaintiff External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Express Scripts
Moodys
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.